Latest Breaking News On - Caitlin kasunich jenny robles - Page 1 : comparemela.com
FDA Grants 510(k) Market Clearance to Vivos Therapeutics mmRNA Oral Appliance for Treating Mild to Moderate Sleep Apnea
forextv.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from forextv.com Daily Mail and Mail on Sunday newspapers.
Detailed Summary of Study Reporting that One in Four Patients Show No Symptoms of Obstructive Sleep Apnea After Vivos Treatment Now Available on Vivos Therapeutics Website
forextv.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from forextv.com Daily Mail and Mail on Sunday newspapers.
Message :
Required fields
Vivos Therapeutics Announces Closing of Follow-On Offering and Exercise in Full of the Underwriters Option to Purchase Additional Shares HIGHLANDS RANCH, Colo., May 11, 2021 - Vivos Therapeutics, Inc. (Nasdaq: VVOS) ( Vivos ), a medical technology company focused on developing and commercializing innovative treatments for patients suffering from sleep-disordered breathing, including mild-to-moderate obstructive sleep apnea (OSA), today announced the closing of its underwritten follow-on public offering of 4,600,000 shares of its common stock. The offering consisted of 4,000,000 shares of its common stock, as well as an additional 600,000 shares pursuant to the exercise in full of the underwriters option to purchase additional shares of common stock, at a public offering price of $6.00 per share.
Vivos Therapeutics Announces Pricing of $24 Million Follow-On Offering
HIGHLANDS RANCH, Colo., May 06, 2021 (GLOBE NEWSWIRE) Vivos Therapeutics, Inc. (Nasdaq: VVOS) (“Vivos”), a medical technology company focused on developing and commercializing innovative treatments for patients suffering from sleep-disordered breathing, including mild-to-moderate obstructive sleep apnea (OSA), today announced the pricing of its underwritten follow-on public offering of 4,000,000 shares of its common stock at a public offering price of $6.00 per share.
The aggregate gross proceeds to Vivos from the public offering are expected to be $24 million prior to deducting underwriting discounts, commissions, and other estimated offering expenses. Vivos has granted the underwriters a 45-day option to purchase up to an additional 600,000 shares of common stock to cover over-allotments, if any.
Press release content from Globe Newswire. The AP news staff was not involved in its creation.
Vivos Therapeutics Announces Closing of Initial Public Offering and Exercise in Full of the .
Vivos Therapeutics, IncDecember 15, 2020 GMT
HIGHLANDS RANCH, Colo., Dec. 15, 2020 (GLOBE NEWSWIRE) Vivos Therapeutics, Inc. (“Vivos”) today announced the closing of its initial public offering of 4,025,000 shares of its common stock. The offering consisted of 3,500,000 shares of its common stock, as well as an additional 525,000 shares pursuant to the exercise in full of the underwriters’ option to purchase additional shares of common stock, at a public offering price of $6.00 per share. Vivos’ common stock is listed on the Nasdaq Capital Market under the ticker symbol “VVOS.”
vimarsana © 2020. All Rights Reserved.